{"schema_version":"1","generated_at":"2026-10-30T20:10:26.596Z","data_as_of":"2026-10-27","url":"https://www.findmykol.com/kol/andrew-cluster","json_url":"https://www.findmykol.com/kol/andrew-cluster/profile.json","record_kind":"full","profile_kind":"clinical","person":{"slug":"andrew-cluster","name":"Andrew Cluster","credential":"MD","title":"Associate Professor of Pediatrics, Division of Hematology/Oncology, WashU Medicine","specialty":"Hematology / Oncology","specialty_raw":"Pediatric Hematology-Oncology","therapeutic_area":"Neuro-Oncology","therapeutic_areas":["Neuro-Oncology","Leukemia"],"institution":"Washington University in St. Louis (WashU Medicine)","institution_url":"https://www.findmykol.com/institution/washington-university-school-of-medicine-in-st-louis","city":"Saint Louis","state":"MO","region":{"label":"Midwest","url":"https://www.findmykol.com/region/midwest"},"country":{"name":"United States","code":"US","status":"verified"}},"identifiers":{"npi":"1245542869","orcid":"0000-0001-8963-7099","openalex":"A5075397468"},"summary":"Andrew Cluster is Associate Professor of Pediatrics, Division of Hematology/Oncology, WashU Medicine at Washington University in St. Louis (WashU Medicine). OpenAlex indexes 66 publications with 678 citations (h-index 11); ClinicalTrials.gov lists 11 registered studies with this person as an investigator.","overview":{"text":"Andrew Cluster, MD, is Associate Professor of Pediatrics, Division of Hematology/Oncology, WashU Medicine at Washington University in St. Louis (WashU Medicine). The public record shows 66 publications with 678 citations (h-index 11), centered on Glioma Diagnosis and Treatment, Acute Myeloid Leukemia Research, Acute Lymphoblastic Leukemia research. It also documents an investigator role on 11 registered clinical trials, industry payments reported by 1 companies.","bullets":["Most recent indexed publication: 2024 · Journal of clinical oncology","Top research focus: Glioma Diagnosis and Treatment","11 registered trials on ClinicalTrials.gov","Open Payments reporting from 1 companies"],"generated_at":"2026-10-28"},"focus":{"indications":[{"label":"Neuro-Oncology / Glioma","therapeutic_area":"Oncology","trials":7,"topics":1,"strength":22},{"label":"Glioma","therapeutic_area":"Oncology","trials":4,"topics":0,"strength":12},{"label":"Astrocytoma","therapeutic_area":"Oncology","trials":2,"topics":0,"strength":6},{"label":"Medulloblastoma","therapeutic_area":"Oncology","trials":2,"topics":0,"strength":6},{"label":"Sarcoma","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Sarcoma, Ewing","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Rhabdomyosarcoma","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Wilms Tumor","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Coma","therapeutic_area":"Neurology","trials":1,"topics":0,"strength":3},{"label":"Retinoblastoma","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Neuroectodermal Tumors, Primitive","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Neuroectodermal Tumors","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Myosarcoma","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Central Nervous System Neoplasms","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Nervous System Neoplasms","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Ependymoma","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Neurofibromatosis 1","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Neurofibromatoses","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Neurofibroma","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Fibroma","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Oligodendroglioma","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Optic Nerve Glioma","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Leukemia (AML/ALL/CML/CLL)","therapeutic_area":"Oncology","trials":0,"topics":2,"strength":2}],"research_topics":["Glioma Diagnosis and Treatment","Acute Myeloid Leukemia Research","Acute Lymphoblastic Leukemia research","Hematopoietic Stem Cell Transplantation","Neurofibromatosis and Schwannoma Cases"],"drugs_studied":{"total":1,"shown":1,"withheld":0,"rows":[{"name":"Ojemda","generic":"Tovorafenib","trials":0,"payments":1,"publications":0,"mentions":1}]},"works_with":{"total":6,"shown":3,"withheld":3,"rows":[{"name":"Washington University School of Medicine","trials":6,"payments":0,"mentions":6},{"name":"National Cancer Institute (NCI)","trials":2,"payments":0,"mentions":2},{"name":"Children's Oncology Group","trials":1,"payments":0,"mentions":1}]}},"scholarship":{"works_count":66,"cited_by_count":678,"h_index":11,"i10_index":11,"pubmed_count":1,"latest_activity_year":2024,"source":"works"},"trials":{"count":11,"shown":3,"withheld":8,"matched_by":"identity-adjudicated record","rows":[{"nct":"NCT07039760","title":"Asciminib With or Without Sildenafil for Brain Tumors","phase":"EARLY_PHASE1","status":"NOT_YET_RECRUITING","role":"Investigator","sponsor":"Washington University School of Medicine","source_url":"https://clinicaltrials.gov/study/NCT07039760","trial_url":"https://www.findmykol.com/trial/NCT07039760"},{"nct":"NCT06541847","title":"A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1","phase":"PHASE2","status":"RECRUITING","role":"Investigator","sponsor":"Healx Limited","source_url":"https://clinicaltrials.gov/study/NCT06541847","trial_url":"https://www.findmykol.com/trial/NCT06541847"},{"nct":"NCT05521984","title":"Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)","phase":"PHASE1","status":"RECRUITING","role":"Investigator","sponsor":"Washington University School of Medicine","source_url":"https://clinicaltrials.gov/study/NCT05521984","trial_url":"https://www.findmykol.com/trial/NCT05521984"}],"source":"trials"},"payments":{"company_count":1,"program_years":{"first":2024,"last":2024},"rows_total":1,"shown":1,"withheld":0,"rows":[{"payer":"Day One Biopharmaceuticals","program_year":2024,"amount_usd":19.76,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1245542869"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1245542869","source":"payments"},"prescribing":{"data_year":2022,"areas_total":1,"areas_shown":1,"areas":[{"area":"Nervous system","share_pct":100,"classes_total":1,"classes":[{"class":"gamma-Aminobutyric Acid A Receptor Positive Modulator","setting":"prescribed","share_pct":100,"drugs":[{"name":"Zolpidem Tartrate","share_pct":100}],"max_beneficiaries":null}]}],"source":"medicare"},"funding":{"award_count":0,"rows_total":0,"shown":0,"withheld":0,"rows":[],"source":"grants"},"publications":{"total":1,"shown":1,"withheld":0,"matched_by":"ORCID record, linked to PubMed","recent":[{"title":"ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma.","year":2024,"journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","types":["Journal Article","Research Support, Non-U.S. Gov't","Research Support, N.I.H., Extramural"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/38335473/","status":"verified"}],"most_cited":{"total":66,"shown":5,"withheld":61,"rows":[{"title":"Calcineurin/NFAT-induced up-regulation of the Fas ligand/Fas death pathway is involved in methamphetamine-induced neuronal apoptosis","year":2005,"cited_by_count":223,"type":"article","source_url":"https://doi.org/10.1073/pnas.0404990102"},{"title":"ONC201 (Dordaviprone) in Recurrent H3 K27M–Mutant Diffuse Midline Glioma","year":2024,"cited_by_count":120,"type":"article","source_url":"https://doi.org/10.1200/jco.23.01134"},{"title":"Unrelated Umbilical Cord Blood Transplantation for Sickle Cell Disease Following Reduced-Intensity Conditioning: Results of a Phase I Trial","year":2017,"cited_by_count":70,"type":"article","source_url":"https://doi.org/10.1016/j.bbmt.2017.05.027"},{"title":"Kmt2c mutations enhance HSC self-renewal capacity and convey a selective advantage after chemotherapy","year":2021,"cited_by_count":36,"type":"article","source_url":"https://doi.org/10.1016/j.celrep.2021.108751"},{"title":"Multi-institutional study of the frequency, genomic landscape, and outcome of IDH-mutant glioma in pediatrics","year":2022,"cited_by_count":33,"type":"article","source_url":"https://doi.org/10.1093/neuonc/noac132"}]},"source":"publications"},"network":{"coauthors_total":40,"shown":3,"withheld":37,"coauthors":[{"name":"Mohamed Shebl Abdelbaki","coauthored_works":34},{"name":"Andrea Ogle","coauthored_works":31,"profile_url":"https://www.findmykol.com/kol/andrea-ogle"},{"name":"Ashley Meyer","coauthored_works":30}],"source":"works"},"presence":{"owned_accounts":{"total":1,"shown":1,"rows":[{"platform":"doximity","url":"https://www.doximity.com/pub/andrew-cluster-md","status":"provisional"}]},"mentions":{"total":2,"shown":2,"rows":[{"url":"https://pnoc.us/?p=1441","platform":"other","status":"provisional"},{"url":"https://siteman.washu.edu/?p=3548","platform":"other","status":"provisional"}]},"verified_means":"confirmed in more than one place; provisional means found and still being confirmed"},"recognition":{"education":{"total":1,"shown":1,"rows":[{"value":"MD, University of Texas Southwestern Medical Center, Dallas, TX (2010)","source_url":"https://siteman.washu.edu/?p=3548","status":"verified","collected_at":"2026-10-28"}]},"roles":{"total":1,"shown":1,"rows":[{"value":"Interim Co-Principal Investigator, Pediatric Neuro-Oncologist (PNOC)","source_url":"https://pnoc.us/?p=1441","status":"provisional","collected_at":"2026-10-28"}]},"secondary_affiliations":{"total":1,"shown":1,"rows":[{"value":"St. Louis Children's Hospital (practice site)","source_url":"https://pnoc.us/?p=1441","status":"provisional","collected_at":"2026-10-28"}]}},"similar":[{"name":"Tanner Johanns","slug":"tanner-johanns","institution":"Washington University in St. Louis (WashU Medicine)","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/tanner-johanns","json_url":"https://www.findmykol.com/kol/tanner-johanns/profile.json"},{"name":"Rithwick Rajagopal","slug":"rithwick-rajagopal","institution":"Washington University in St. Louis (WashU Medicine)","specialty":"Retina Specialist","url":"https://www.findmykol.com/kol/rithwick-rajagopal","json_url":"https://www.findmykol.com/kol/rithwick-rajagopal/profile.json"},{"name":"Guy McKhann","slug":"guy-mckhann","institution":"Emory University School of Medicine","specialty":"Neurological Surgery","url":"https://www.findmykol.com/kol/guy-mckhann","json_url":"https://www.findmykol.com/kol/guy-mckhann/profile.json"},{"name":"Patrick Wen","slug":"patrick-wen","institution":"Dana-Farber Cancer Institute","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/patrick-wen","json_url":"https://www.findmykol.com/kol/patrick-wen/profile.json"},{"name":"Minesh Mehta","slug":"minesh-mehta","institution":"Florida International University Herbert Wertheim College of Medicine","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/minesh-mehta","json_url":"https://www.findmykol.com/kol/minesh-mehta/profile.json"},{"name":"Timothy Cloughesy","slug":"timothy-cloughesy","institution":"Ronald Reagan UCLA Medical Center","specialty":"Neurology","url":"https://www.findmykol.com/kol/timothy-cloughesy","json_url":"https://www.findmykol.com/kol/timothy-cloughesy/profile.json"}],"coverage":{"note":"An identity-adjudicated profile: every section above was checked. Where a section states a count of zero, the public record was searched and nothing was found."},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"trials":8,"network":37}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts","collected_at":"2026-10-28"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies","collected_at":"2026-10-28"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2024 to 2024","collected_at":"2026-10-28"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2022},"grants":{"name":"NIH RePORTER","url":"https://reporter.nih.gov","provides":"Federally funded research awards, by fiscal year"},"publications":{"name":"PubMed (NLM)","url":"https://pubmed.ncbi.nlm.nih.gov","provides":"Peer-reviewed publications, linked to the PubMed record","collected_at":"2026-10-28"}},"methodology_url":"https://www.findmykol.com/about#methodology"}